# Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

> **NCT00521261** · PHASE1 · WITHDRAWN · sponsor: **Barbara Ann Karmanos Cancer Institute**

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells

## Key facts

- **NCT ID:** NCT00521261
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2007-10
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2014-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00521261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00521261, "Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00521261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*